TRDA Q4 2024 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M-10.6% YoY

Gross Profit

$37M100.0% margin

Operating Income

-$6M-15.7% margin

Net Income

$1M3.0% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+91.1%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$526M

Total Liabilities

$98M

Stockholders' Equity

$429M

Cash & Equivalents

$101M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$42M	-10.6%
Gross Profit	$37M	$42M	-10.6%
Operating Income	-$6M	$5M	-219.6%
Net Income	$1M	-$10M	+111.9%